Here are the 424B prospectus supplements from Amgen Inc (AMGN) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow AMGN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AMGN filings page.
Amgen Inc. is offering four series of senior unsecured notes: $1,000,000,000 4.200% Senior Notes due 2031; $1,750,000,000 4.850% Senior Notes due 2036; $500,000,000 5.500% Senior Notes due 2046; and $750,000,000 5.650% Senior Notes due 2056.
Interest on each series is payable semi-annually in cash on February 19 and August 19, beginning August 19, 2026. The notes are senior unsecured obligations ranking equally with Amgen's other senior unsecured indebtedness and will be issued in book-entry form through DTC, with expected delivery on or about February 19, 2026. Net proceeds of approximately $3,961,495,000 are intended to repay specified 2026 maturities, repay borrowings under the Term Loan Credit Agreement, and for general corporate purposes, subject to the use-of-proceeds disclosure.
Amgen Inc. plans a multi-tranche offering of senior unsecured notes maturing in 2031, 2036, 2046 and 2056. The notes will pay cash interest semi-annually, rank equally with Amgen’s existing senior unsecured debt and may be redeemed early at specified make-whole or par prices.
Amgen expects to use the net proceeds to refinance near-term obligations, including its 2.00% Senior Notes due 2026 with €750 million outstanding, 2.60% Senior Notes due 2026 with $1.25 billion outstanding, a $1.8 billion term loan due 2026, and a portion of its 5.50% Senior Notes due 2026 with £475 million outstanding, with any remaining proceeds applied to other indebtedness and general corporate purposes.